A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07769502

Title field or adapter rule

{'original_value': 'A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.523101+00:00

Published At

2026-10-13T00:00:00+00:00

Record Updated At

2026-10-13

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatobiliary Cancers", "Pancreatic Ductal Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-13", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07769502"

protocolSection.identificationModule.officialTitle

"A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Pancreatobiliary Cancers (AndroMETa-118)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatobiliary Cancers (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['SS1: Dose Escalation: Telisotuzumab Adizutecan + Gemcitabine', 'SS1:DoseOptimization:TelisotuzumabAdizutecan+Gemcitabine DoseA', 'SS1:DoseOptimization:TelisotuzumabAdizutecan+GemcitabineDoseB'], 'description': 'Intravenous (IV) Infusion', 'name': 'Telisotuzumab Adizutecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['SS1: Dose Escalation: Telisotuzumab Adizutecan + Gemcitabine', 'SS1: Dose Optimization: Standard of Care (SOC)', 'SS1:DoseOptimization:TelisotuzumabAdizutecan+Gemcitabine DoseA', 'SS1:DoseOptimization:TelisotuzumabAdizutecan+GemcitabineDoseB'], 'description': 'Intravenous (IV) Infusion', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['SS1: Dose Optimization: Standard of Care (SOC)'], 'description': 'Intravenous (IV) Infusion', 'name': 'Nab-Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Telisotuzumab Adizutecan (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)
• Nab-Paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.